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Background
While the effects of the bacterial component and Toll-like
receptor-4 (TLR4) agonist, lipopolysaccharide (LPS), on
affective behaviour is well described, there is a lack of data
concerning the effects of peptidoglycans on behaviour.
Amongst others, peptidoglycans activate the intracellular
receptors nucleotide-binding oligomerization domain 1
(NOD1) and NOD2. Here, the effects of the NOD1 activa-
tor FK565 and NOD2 activator muramyl dipeptide (MDP)
were investigated with respect to parameters of immune
activation and behaviour.
Methods
Male C57BL/6N mice received an intraperitoneal injection
of FK565 (0.003 mg/kg), MDP (3 mg/kg) or sterile saline
(0.9% NaCl) and an additional injection of LPS (0.83 mg/
kg) or sterile saline 4 hours after the first injection. Body
weight and rectal temperature were monitored throughout
the study. Exploratory and anxiety-like behaviour was eval-
uated with the open field test (OFT) 1 day and with the
step-down test 2 days after treatment. Spleen weight, an
index of immune activation, was measured on the third
day after sacrifice of mice.
Results
While none of the single treatments induced changes of
body temperature, combined treatment with FK565+LPS
and MDP+LPS caused a decrease of body temperature
4.5 hours post-treatment. A loss of body weight could be
observed in the LPS, FK565+LPS and MDP+LPS-treated
groups on day 1 and 2, while FK565 and MDP alone had
no effect on body weight. On the third day post-treatment,
the weight loss was gone in the LPS treated group, but was
still evident in the groups receiving the double treatments.
In the OFT, only treatment with FK565+LPS or MDP+LPS
decreased travelling distance and visits to the central area.
Likewise, in the step-down test only the double-treated
mice presented an increased latency. LPS alone and in
combination with FK565 or MDP increased spleen weight
while FK565 and MDP alone were without effect.
Conclusions
The present results reveal that administration of a NOD1
or NOD2 activator alone fails to induce any systemic signs
of immune activation, sickness (weight loss) and beha-
vioural disturbance. In contrast, mice primed with either
FK565 or MDP display increased anxiogenic and immune
reactions to LPS. These findings indicate that NOD and
TLR-4 agonists synergize in vivo in causing immune acti-
vation and sickness behaviour.
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